ArticleCureus2025
Gemcitabine-Induced Thrombotic Microangiopathy in a Patient With Metastatic Pancreatic Cancer: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic microangiopathies (TMA) are potentially life-threatening conditions caused by small-vessel platelet thrombi. Gemcitabine has been reported to induce TMA. Early detection and treatment of gemcitabine-induced TMA (GiTMA) are important to improve overall mortality. This case details a 65-year-old female with metastatic pancreatic acinar cell carcinoma who was treated with gemcitabine. The patient presented with acute kidney injury, hemolytic anemia (requiring transfusion), and thrombocytopenia. She underwent a renal biopsy, which was consistent with thrombotic microangiopathy in the subacute to chronic phase. The patient was initially treated with eculizumab, followed by a transition to ravulizumab due to the latter's less frequent dosing. Eculizumab and ravulizumab are both monoclonal antibodies targeting complement protein C5, subsequently inhibiting the terminal complement cascade and reducing inflammation and tissue injury. This case highlights the importance of recognizing GiTMA and discusses the use of complement inhibitors in its management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.